Your browser is no longer supported. Please, upgrade your browser.
Settings
SEEL Seelos Therapeutics, Inc. daily Stock Chart
SEEL [NASD]
Seelos Therapeutics, Inc.
Index- P/E- EPS (ttm)-12.71 Insider Own16.50% Shs Outstand20.59M Perf Week-2.94%
Market Cap54.36M Forward P/E- EPS next Y-1.10 Insider Trans- Shs Float14.89M Perf Month-12.00%
Income-9.20M PEG- EPS next Q-0.18 Inst Own10.70% Short Float9.30% Perf Quarter13.79%
Sales- P/S- EPS this Y59.10% Inst Trans-66.97% Short Ratio0.28 Perf Half Y-70.18%
Book/sh2.74 P/B0.96 EPS next Y- ROA-163.80% Target Price4.00 Perf Year-69.71%
Cash/sh0.17 P/C15.10 EPS next 5Y- ROE-227.40% 52W Range1.32 - 17.40 Perf YTD-54.17%
Dividend- P/FCF- EPS past 5Y38.60% ROI- 52W High-84.83% Beta0.77
Dividend %- Quick Ratio3.10 Sales past 5Y- Gross Margin- 52W Low100.00% ATR0.16
Employees5 Current Ratio3.10 Sales Q/Q- Oper. Margin- RSI (14)38.97 Volatility5.75% 5.26%
OptionableNo Debt/Eq0.00 EPS Q/Q61.50% Profit Margin- Rel Volume0.03 Prev Close2.64
ShortableYes LT Debt/Eq0.00 EarningsMay 23 Payout- Avg Volume4.89M Price2.64
Recom2.00 SMA20-7.17% SMA50-9.66% SMA200-58.46% Volume135,695 Change0.00%
May-14-19Initiated ROTH Capital Buy
May-21-19 08:30AM  Seelos Therapeutics Reports Q1 2019 Pipeline Update GlobeNewswire
Apr-16-19 08:00AM  Seelos Therapeutics to Participate at the Jefferies 2019 Global Healthcare Conference in NYC GlobeNewswire
Apr-02-19 01:15PM  Two Months into a Reverse Merger, Where Does Seelos Therapeutics Stand Now? ACCESSWIRE
Mar-29-19 02:43PM  Why Seelos Therapeutics Shares Are Surging Out Of The Gate Benzinga +17.48%
Mar-28-19 05:00PM  Seelos Therapeutics Provides Update on Pipeline Developments and Corporate Highlights GlobeNewswire
Mar-27-19 09:25AM  Four Healthcare Stocks Picking Up Speed on Wednesday ACCESSWIRE
Mar-13-19 07:30AM  A Near Term FDA Clearance That Could Be The Beginning Of The Brain-Computer Revolution? ACCESSWIRE -14.29%
Mar-08-19 09:37AM  Shares of Seelos Therapeutics up 80% Friday morning MarketWatch +11.51%
09:35AM  Four Healthcare Stocks Looking To Close Out a Strong Week on Friday ACCESSWIRE
Mar-07-19 08:00AM  Seelos Therapeutics Announces Acquisition of an Exclusive License to Intellectual Property from The UC Regents to Potential Disease-Modifying Parkinson's Disease Therapy Created at UCLA GlobeNewswire +96.13%
Mar-06-19 02:45PM  Four Tech Stocks To Watch on Wednesday ACCESSWIRE
08:00AM  Seelos Therapeutics to Webcast Presentation at the 39th Annual Cowen Health Care Conference and Participate in the 31st Annual ROTH Conference GlobeNewswire
Mar-01-19 09:00AM  Seelos Therapeutics to Present at the 39th Annual Cowen Health Care Conference GlobeNewswire -13.51%
Feb-19-19 08:00AM  Seelos Therapeutics Completes Acquisition of Trehalose from Bioblast Pharma GlobeNewswire -5.99%
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients. The company was founded in 2016 and is based in New York, New York.